MX9204077A - Estimulacion anti-cd3 a corto plazo de linfocitos para incrementar su actividad in vivo. - Google Patents

Estimulacion anti-cd3 a corto plazo de linfocitos para incrementar su actividad in vivo.

Info

Publication number
MX9204077A
MX9204077A MX9204077A MX9204077A MX9204077A MX 9204077 A MX9204077 A MX 9204077A MX 9204077 A MX9204077 A MX 9204077A MX 9204077 A MX9204077 A MX 9204077A MX 9204077 A MX9204077 A MX 9204077A
Authority
MX
Mexico
Prior art keywords
lymphocytes
vivo
stimulation
activity
short
Prior art date
Application number
MX9204077A
Other languages
English (en)
Inventor
Dan L Longo
Augusto C Ochoa
Cynthia Loeffler
Walter Urea
Original Assignee
Dan L Longo
Augusto C Ochoa
Cynthia Loeffler
Walter Urea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dan L Longo, Augusto C Ochoa, Cynthia Loeffler, Walter Urea filed Critical Dan L Longo
Publication of MX9204077A publication Critical patent/MX9204077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está dirigida a un método para incrementar la respuesta inmulógica in vivo de linfocitos mediante la estimulación de los linfocitos in vitro en presencia de un anticuerpo monoclonal anti-CD3 por menos de alrededor de 24 horas para formar linfocitos estimulados; infundir los linfocitos estimulados en un mamíferos portador de un tumor; y administrar IL-2 al mamífero. Como resultado de este método, los linfocitos estimulados anti-CD3 exhiben una mejorada producción inmunoterapéutica, por ejemplo citotoxicidad o de linfoquina in vivo, como se representa por una reducción en el número de tumores de al menos alrededor de 20.
MX9204077A 1991-07-10 1992-07-10 Estimulacion anti-cd3 a corto plazo de linfocitos para incrementar su actividad in vivo. MX9204077A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72810791A 1991-07-10 1991-07-10

Publications (1)

Publication Number Publication Date
MX9204077A true MX9204077A (es) 1994-06-30

Family

ID=24925447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9204077A MX9204077A (es) 1991-07-10 1992-07-10 Estimulacion anti-cd3 a corto plazo de linfocitos para incrementar su actividad in vivo.

Country Status (12)

Country Link
US (1) US5316763A (es)
EP (1) EP0593625B1 (es)
JP (1) JP3507489B2 (es)
AT (1) ATE142885T1 (es)
AU (1) AU674128B2 (es)
CA (1) CA2111564A1 (es)
DE (1) DE69213943T2 (es)
IE (1) IE922233A1 (es)
IL (1) IL102460A (es)
MX (1) MX9204077A (es)
WO (1) WO1993000918A1 (es)
ZA (1) ZA925155B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
EP0440742B1 (en) * 1988-10-27 1997-01-15 The Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
WO1995020649A1 (en) * 1994-01-27 1995-08-03 Cellcor, Inc. Ex vivo activation of immune cells
WO1995032729A1 (en) * 1994-05-31 1995-12-07 Augusto Carlos Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity
US5723503A (en) * 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
WO1996040176A1 (en) * 1995-06-07 1996-12-19 Sloan-Kettering Institute For Cancer Research Therapeutic uses of monoclonal antibody ta99 in combination with interleukin-2 and/or lymphokine activated killer cells
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
IL125747A0 (en) * 1996-10-04 1999-04-11 Univ Jefferson T cells mediating an immune response and methods of use
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
JP6074916B2 (ja) * 2012-05-22 2017-02-08 東洋製罐グループホールディングス株式会社 細胞活性化方法、及び細胞培養方法
CN107502589A (zh) * 2017-08-04 2017-12-22 北京世纪劲得生物技术有限公司 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049611B2 (en) * 1980-10-02 1993-12-08 Hooper Trading Co. N.V. A T-cell growth factor, and a process of producing the same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8405555D0 (en) * 1984-03-02 1984-04-04 Rees A D M Macrophage activating factors
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
EP0203403B1 (en) * 1985-05-01 1992-10-28 Asahi Kasei Kogyo Kabushiki Kaisha A cloned t cell capable of recognizing tumors and a t cell antigen receptor
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
US4882424A (en) * 1987-05-11 1989-11-21 Dana-Farber Cancer Institute, Inc. Activation antigen
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
WO1989009831A1 (en) * 1988-04-15 1989-10-19 Research Corporation Technologies, Inc. Lak cell cytotoxin
WO1990004633A1 (en) * 1988-10-21 1990-05-03 Brigham And Women's Hospital ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
EP0440742B1 (en) * 1988-10-27 1997-01-15 The Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer

Also Published As

Publication number Publication date
EP0593625A4 (en) 1994-11-02
EP0593625B1 (en) 1996-09-18
ATE142885T1 (de) 1996-10-15
EP0593625A1 (en) 1994-04-27
ZA925155B (en) 1993-04-28
IL102460A0 (en) 1993-01-14
AU2300592A (en) 1993-02-11
IL102460A (en) 2001-08-26
DE69213943D1 (de) 1996-10-24
CA2111564A1 (en) 1993-01-21
DE69213943T2 (de) 1997-04-10
JPH07502486A (ja) 1995-03-16
US5316763A (en) 1994-05-31
AU674128B2 (en) 1996-12-12
WO1993000918A1 (en) 1993-01-21
JP3507489B2 (ja) 2004-03-15
IE922233A1 (en) 1993-01-13

Similar Documents

Publication Publication Date Title
MX9204077A (es) Estimulacion anti-cd3 a corto plazo de linfocitos para incrementar su actividad in vivo.
Boyman et al. Modulation of T cell responses by IL-2 and IL-2 complexes
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
JP7268039B2 (ja) がん治療のためのナチュラルキラー細胞および組成物の製造方法
RU94034104A (ru) Способ увеличения цитотоксичности химиотерапевтического агента, набор для лечения и средство для производства лекарств
DE69433590D1 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
JPH06501017A (ja) 充実性腫瘍の処置のためのｉｌ−４の使用
BG47037A3 (en) Method for preparing of derivatives of 1h, 3h- pyrolo /1, 2- c/ thiazol
ATE71662T1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
BG47038A3 (en) Method for preparing of derivatives of 1h, 3h- pyrolo /1, 2- c/ thiazol
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
DE69110060D1 (de) In der humantherapie nützliche substanzen peptidischer natur.
ES458197A1 (es) Un procedimiento para la preparacion de nuevos peptidoglica-nos.
NZ224116A (en) Compositions of interleukin-2 and fk565; method of stimulation of the immune system and package
Eguchi et al. Interferon-α and interleukin-12 gene therapy of cancer: interferon-α induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing
ES2039236T3 (es) Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral.
Metwali et al. IL-2 contributes to the IL-5 response in granulomas from mice infected with Schistosoma mansoni.
ES8800981A1 (es) Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo
Nakano et al. Augmentation of the generation of cytotoxic T lymphocytes against syngeneic tumor cells by recombinant human tumor necrosis factor
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
DE19721211A1 (de) Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren
RU94045922A (ru) Противоопухолевый цитокин, способ его получения, способ его очистки, фармацевтическая композиция на его основе, иммуномодулятор и фактор роста
Trinchieri Interleukin-12: Clinical Potential in Infectious Diseases, AIDS and Cancer
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees